renal cell carcinoma

You have access
Pimitespib, a Novel Heat Shock Protein 90 Inhibitor, Is Effective in Treating Renal Cell Carcinoma by Anti-angiogenetic Signaling
RYUGO TERANISHI, TSUYOSHI TAKAHASHI, YUKINORI KUROKAWA, TAKURO SAITO, KAZUYOSHI YAMAMOTO, KOTA MOMOSE, KOTARO YAMASHITA, KOJI TANAKA, TOMOKI MAKINO, KIYOKAZU NAKAJIMA, HIDETOSHI EGUCHI and YUICHIRO DOKI

Anticancer Research August 2024, 44 (8) 3343-3348; DOI: https://doi.org/10.21873/anticanres.17154
You have access
Down-regulation of ABCB1 in Everolimus-resistant Renal Cell Carcinoma Cells
YUKO NAKAYAMA, AYA INO, KAZUHIRO YAMAMOTO and KOHJI TAKARA

Anticancer Research July 2024, 44 (7) 2871-2876; DOI: https://doi.org/10.21873/anticanres.17099
You have access
Effect of Acridine Orange and Zoledronic Acid on Bone Metastasis in Renal Cell Carcinoma
KEITA OYA, HIROYUKI TSUCHIE, HIROYUKI NAGASAWA, MICHIO HONGO, YUJI KASUKAWA, DAISUKE KUDO, RYO SHOJI, FUMIHITO KASAMA, TAKASHI KAWARAGI, MANABU WATANABE, KENTA TOMINAGA and NAOHISA MIYAKOSHI

Anticancer Research June 2024, 44 (6) 2487-2495; DOI: https://doi.org/10.21873/anticanres.17055
You have access
Associations of Matrix Metalloproteinase-8 Genotypes to Renal Cell Carcinoma in Taiwan
CHENG-HSI LIAO, WEI-CHING CHIEN, SHU-YU CHANG, YU-HSIN LIN, YUN-CHI WANG, WEN-CHIN HUANG, MEI-CHIN MONG, YA-CHEN YANG, WEN-TZU WU, JAW-CHYUN CHEN, CHAO-HSIANG CHANG, CHIA-WEN TSAI, DA-TIAN BAU and WEN-SHIN CHANG

Anticancer Research May 2024, 44 (5) 1931-1938; DOI: https://doi.org/10.21873/anticanres.16995
Open Access
TCR CDR3-CMV Antigen Chemical Complementaries Are Associated With a Worse Outcome for Renal Cell Carcinoma
LILA ALKASSAB, MICHAEL J. DIAZ, ELIZABETH A. FETCHER, TAHA I. HUDA, SRIJIT PAUL, SHIVANSHU KUMAR, ANDREA CHOBRUTSKIY, BORIS I. CHOBRUTSKIY, JOANNA J. SONG and GEORGE BLANCK

Anticancer Research April 2024, 44 (4) 1505-1511; DOI: https://doi.org/10.21873/anticanres.16947
You have access
Advanced Renal Cell Carcinoma With Inferior Vena Cava Thrombus Treated With a Combination of Preoperative Lenvatinib and Pembrolizumab
CHIKA NAGAHISA, KAZUHIKO YOSHIDA, HANAE KONDO, TAKAYUKI NAKAYAMA, SHINSUKE MIZOGUCHI, RYO MINODA, HIRONORI FUKUDA, YUKI KOBARI, JUNPEI IIZUKA, YOJI NAGASHIMA, HIDEKI ISHIDA and TOSHIO TAKAGI

Anticancer Research March 2024, 44 (3) 1317-1321; DOI: https://doi.org/10.21873/anticanres.16927
You have access
Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma
RYO SATO, YUTO MATSUSHITA, AYANA TAKEMURA, MOMOKO SUGIYAMA, KYOHEI WATANABE, HIROMITSU WATANABE, KEITA TAMURA, DAISUKE MOTOYAMA, MASAO NAGATA, ATSUSHI OTSUKA, HIROSHI FURUSE and HIDEAKI MIYAKE

Anticancer Research February 2024, 44 (2) 781-786; DOI: https://doi.org/10.21873/anticanres.16869
You have access
Efficacy of Sunitinib in Patients With Favorable and Intermediate Risk Metastatic Renal Cell Carcinoma – Lithuanian National Cancer Institute Experience
ALGIRDAS ZALIMAS, VINCAS URBONAS, DAIVA DABKEVICIENE, JONAS PURVANECKAS, ALBERTAS ULYS and SONATA JARMALAITE

Anticancer Research January 2024, 44 (1) 213-219; DOI: https://doi.org/10.21873/anticanres.16804
You have access
Discontinuation of Immune-oncology Combinations due to Immune-related Adverse Events in Patients With Advanced Renal Cancers
KENSUKE BEKKU, MANUELA SCHMIDINGER, SATOSHI KATAYAMA, TATSUSHI KAWADA, TAKAFUMI YANAGISAWA, TAKEHIRO IWATA, KOHEI EDAMURA, TOMOKO KOBAYASHI, YASUYUKI KOBAYASHI, MOTOO ARAKI and SHAHROKH F. SHARIAT

Anticancer Research January 2024, 44 (1) 379-386; DOI: https://doi.org/10.21873/anticanres.16822
Open Access
Molecular Characteristics of Everolimus-resistant Renal Cell Carcinoma Cells Generated by Continuous Exposure to Everolimus
YUKO NAKAYAMA, DAICHI ENOMOTO, KAZUHIRO YAMAMOTO and KOHJI TAKARA

Anticancer Research October 2023, 43 (10) 4349-4357; DOI: https://doi.org/10.21873/anticanres.16630

Main menu

User menu

Search

renal cell carcinoma

Pages